DLBCL

A presentation at ESMO 2022 explains the use of circulating tumor DNA as a tool which can predict outcomes for patients with diffuse large B-cell lymphoma.

The combination of orelabrutinib plus the R-CHOP regimen revealed a positive overall response rate of 86.4% when given to patients with non-germinal center B cell-like diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses his experience using the combination of polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

In a study, a correlation between frailty status and death at 1 year was identified in patients with diffuse large B-cell lymphoma.

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

A high overall response rate was demonstrated with epcoritamab treatment in patients with diffuse large B-cell lymphoma, according to results from the phase 1/2 EPCORE NHL-2 trial.

Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Dipenkumar Modi, MD, and participants discussed the leading later-line therapy options for patients with diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable discussion, Mehdi H. Hamadani, MD, discussed systemic therapy options for relapsed/refractory diffuse large B-cell lymphoma.

Dr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.

An expert describes factors for consideration when choosing a second-line treatment for relapsed DLBCL.

Grzegorz S. Nowakowski, MD, reviews the approved further-line treatment options for relapsed DLBCL.

An explanation of the design, efficacy, and adverse events of L-MIND, a trial investigating a combination treatment for R/R DLBCL.

Dr Grzegorz S. Nowakowski reviews the currently available second-line treatment options for transplant-ineligible R/R DLBCL.

A discussion on the clinical factors that put patients at risk of having relapsed DLBCL.

Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Stephen Ansell, MD, PhD, discussed the options for third-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.